Press Releases

May 11, 2021
Praxis Precision Medicines Announces Proposed Public Offering of Common Stock
May 11, 2021
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results
April 30, 2021
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE
April 29, 2021
Praxis Precision Medicines Adds Neurology Expertise to Board of Directors with Appointment of Merit Cudkowicz, M.D.
April 15, 2021
Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of Jeffrey Chodakewitz, M.D.
April 14, 2021
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEE
Displaying 1 - 10 of 15